Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317636 | 0.83 | ALDH1A1 (0.51) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL5128161 | 0.83 | LMNA (0.37) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL2368942 | 0.80 | LMNA (0.36) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL11319827 | 0.77 | MAPK1 (0.39) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL7514705 | 0.76 | ESR1 (0.53) | LMNAKDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7167188 | 0.74 | GAA (0.50) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL2369505 | 0.72 | ALDH1A1 (0.64) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL2369192 | 0.70 | ALDH1A1 (0.48) | LMNAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1604779 | 0.69 | LIMK1 (0.61) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL7096009 | 0.69 | KDM4E (0.52) | LMNAKDM4EALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816351-B2 | 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus | EQUISPHARM CO., LTD (KR) | 2010-10-19 | — | — | US | claimed |
| EP-1928884-B1 | 5,6-DIMETHYLTHIENO[2,3-DI]PYRIMIDINE DERIVATIVES, THE PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTI-VIRUS | EQUISPHARM CO LTD (KR) | 2010-01-13 | — | — | EP | claimed |
| US-20080234482-A1 | 5,6-Dimethylthieno[2,3-Di] Pyrimidine Derivatives, the Preparation Method Thereof and the Pharmaceutical Composition Comprising the Same for Anti-Virus | EQUISPHARM CO., LTD (KR) | 2008-09-25 | — | — | US | claimed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | Global Blood Therapeutics, Inc (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| US-5948911-A | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0934321-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GmbH (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998017668-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-4284773-A | ANTICOAGULANTS | DAIICHI SEIYAKU CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| EP-0008408-A1 | 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions | DAIICHI SEIYAKU CO., LTD. (JP) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | LMNA 1425/4885KDM4E 4699/4885ALDH1A1 918/4885 |
| US-20080234482-A1 | 5,6-Dimethylthieno[2,3-Di] Pyrimidine Derivatives, the Preparation Method Thereof and the Pharmaceutical Composition Comprising the Same for Anti-Virus | DUS2, DPYD, DUT | LMNA 4297/4885KDM4E 1115/4885ALDH1A1 368/4885 |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | LMNA 2258/4885KDM4E 4576/4885ALDH1A1 1007/4885 |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | HAMP, TFRC, SLC40A1 | LMNA 1020/4885KDM4E 4573/4885ALDH1A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.